Journal profile · Biochemistry, Genetics and Molecular Biology-Cancer Research
Molecular and Cellular Oncology
ISSN 2372-3556 · Taylor & Francis · United Kingdom
Molecular and Cellular Oncology: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.1 (journal website); fully open access; APC about USD 1,680; median 82 days to acceptance (21 articles, last 24 months); acceptance rate 15% (journal website); 11 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
Molecular and Cellular Oncology is published by Taylor & Francis and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are DNA Repair Mechanisms, Epigenetics and DNA Methylation and Cancer, Hypoxia, and Metabolism, together about 21.6% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Please note, from 2022 the Print ISSN is not in active use as this journal is no longer published in print. Molecular & Cellular Oncology is an international journal publishing fundamental, translational and clinical research on all aspects of oncogenesis, tumor progression and therapeutic strategies. Topics covered include: All solid and hematological cancers; Mechanistic insights into molecular pathways and cellular processes; Cell growth regulation, signal transduction, and apoptosis; Tumor microenvironment and immunosurveillance; Transcriptomics, proteomics, and metabolomics. Molecular & Cellular Oncology publishes original research, reviews, short articles, commentaries, and author views. *Please note that Molecular & Cellular Oncology converted to a full Open Access journal from Volume 9 (2022). Publication office: Taylor & Francis, Inc., 530 Walnut Street, Suite 850, Philadelphia, PA 19106.
From the journal's Aims & Scope
Research area (LetPub): Biochemistry, Genetics and Molecular Biology-Cancer Research
Editor-in-chief Lorenzo GalluzziPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- DNA Repair MechanismsBiochemistry, Genetics and Molecular Biology7.3%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology7.2%
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology7.1%
- Cancer-related Molecular PathwaysMedicine7.1%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology6.2%
- Autophagy in Disease and TherapyMedicine6.1%
- Ubiquitin and proteasome pathwaysBiochemistry, Genetics and Molecular Biology6%
- Microtubule and mitosis dynamicsBiochemistry, Genetics and Molecular Biology4.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PMCPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 2.1Publisher website ·
- 5-year impact factor (publisher) 2025
- 2.5Publisher website ·
- CiteScore 2026-06
- 3LetPub ·
- CiteScore (publisher) 2025
- 3Publisher website ·
- SJR 2026-06
- 0.62LetPub ·
- SJR (publisher) 2025
- 0.62Publisher website ·
- SNIP 2026-06
- 0.4LetPub ·
- SNIP (publisher) 2025
- 0.4Publisher website ·
- h-index
- 46OpenAlex ·
- i10-index
- 359OpenAlex ·
- 2-year mean citedness
- 2.58OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Volume
- Articles per year (publisher)
- 3Publisher website ·
- Downloads per year (publisher)
- 192,000Publisher website ·
Articles by year OpenAlex count · 1,035 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 9 | 9 | 3 |
| 2025 | 11 | 11 | 16 |
| 2024 | 11 | 11 | 61 |
| 2023 | 4 | 4 | 25 |
| 2022 | 18 | 18 | 108 |
| 2021 | 91 | 91 | 436 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
82 daysMedian, submission to acceptance · P25–P75 62 days – 126 days
- Acceptance to online
- median 13 days (21 articles)
- Submission to online
- median 111 days
- Sample
- 21 articles with submission and acceptance dates (21 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 6 weeksLetPub ·
- Acceptance rate (publisher)
- 15%Publisher website ·
- Submission to first decision
- 20 daysPublisher website ·
- First decision after review
- 45 daysPublisher website ·
- Submission to publication (journal-reported)
- about 6 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 1,615 / USD 1,680 / GBP 1,344 | Yes | CC BY, CC BY-NC | |
| OpenAlex | GBP 1,250 / USD 1,590 / EUR 1,450 | — | — | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted5
- author viewsMolecular & Cellular Oncology publishes original research, reviews, short articles, commentaries, and author views.Length not stated
- commentariesMolecular & Cellular Oncology publishes original research, reviews, short articles, commentaries, and author views.Length not stated
- original researchMolecular & Cellular Oncology publishes original research, reviews, short articles, commentaries, and author views.Length not stated
- reviewsMolecular & Cellular Oncology publishes original research, reviews, short articles, commentaries, and author views.Length not stated
- short articlesMolecular & Cellular Oncology publishes original research, reviews, short articles, commentaries, and author views.Length not stated
Policy excerpts from the journal's websiteOpen access, Peer review
- Open access Open access
Open access journal; only publishes open access articles. Model summary
Molecular & Cellular Oncology is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research. Why choose open access? Increase the discoverability and readership of your article Make an impact and reach new readers, not just…
Source ↗Publisher website ·- Peer review
No longer published in print from 2022. Model summary
Please note, from 2022 the Print ISSN is not in active use as this journal is no longer published in print.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Taylor & Francis
- Country or region
- United Kingdom
- Language
- English
- ISSN
- 2372-3556
- Latest issue on the website
- Volume 13, Issue 1 (2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Molecular and Cellular Oncology
What CAS zone is Molecular and Cellular Oncology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Molecular and Cellular Oncology is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Molecular and Cellular Oncology?
The journal's website gives an impact factor of 2.1 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 3, h-index 46.
How long does peer review take at Molecular and Cellular Oncology?
Based on the dates recorded on 21 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 82 days (interquartile range 62–126 days); authors report an average review time of about 6 weeks; the journal's website gives an acceptance rate of 15%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Molecular and Cellular Oncology?
According to LetPub and DOAJ records, Molecular and Cellular Oncology is indexed in Scopus and DOAJ. The journal's website also lists PMC; that list has not been checked against each database.
Is Molecular and Cellular Oncology open access, and what is the APC?
Molecular and Cellular Oncology is a fully open-access journal. APC about USD 1,680.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .